Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib
Known disorder affecting gastrointestinal absorption
Gastrointestinal disorder affecting absorption or the ability to swallow tablets
Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib
Any known gastrointestinal disorder determined by the investigator that interferes with the absorption of rucaparib
Gastrointestinal (GI) disorder that negatively affects absorption
Severe gastrointestinal disorder
Gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment.
Gastrointestinal disorder affecting absorption (e.g., gastrectomy)
Existing gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease, or previous bowel resection which is considered to be clinically significant or could interfere with absorption.
Gastrointestinal disorder affecting absorption.
No gastrointestinal (GI) disorder that negatively affects absorption
Clinically active existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohnâ€™s disease
Gastrointestinal disorder affecting absorption
Gastrointestinal disorder affecting absorption
An active gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease, uncontrolled celiac)
A gastrointestinal disorder that may affect the absorption of study medication.
Gastrointestinal disorder or abnormality that would interfere with absorption of the study drug
Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months, inflammatory bowel disease)
Pre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
Gastrointestinal disorder affecting absorption
Clinical evidence of uncontrolled malabsorption and/or any other gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with the absorption of rucaparib
Gastrointestinal disorder affecting absorption
Gastrointestinal disorder affecting absorption;
Pre-existing duodental stent and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of study drug.
Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug
Subject has a gastrointestinal disorder affecting absorption.
Any gastrointestinal disorder expected to limit absorption of ibrutinib
Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)
Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent
Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent
Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent
No gastrointestinal (GI) disorder that negatively affects absorption
Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)
History of gastrointestinal disorder or prior extensive gastrointestinal surgery that may interfere with sufficient absorption of the study compounds.
Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease) within last 3 months
Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months).
Gastrointestinal disorder affecting absorption.
Significant gastrointestinal disorder(s), in the opinion of the investigator, that may influence drug absorption
Any gastrointestinal disorder expected to limit absorption of ibrutinib
Gastrointestinal disorder affecting absorption.
Gastrointestinal disorder affecting absorption.
Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)
